Chimeric Therapeutics R&D Tax Incentive Announcement

Chimeric Therapeutics (ASX:$CHM) has received a research and development (R&D) tax refund of A$7,357,688 under the Australian Government's R&D tax incentive. The refund is in recognition of Chimeric's R&D activities during the 2023 financial year and will provide important funding for continued development of its portfolio of cell therapies.

Chimeric Therapeutics Executive Commentary

We are pleased to announce the receipt of the A$7.36M R&D tax refund, which reflects the recognition of our commitment to advancing cell therapies for cancer patients. This funding will be instrumental in furthering the development of our innovative cell therapy portfolio, including our promising CAR T and NK cell therapies. We remain dedicated to bringing the promise of cell therapy to life for more patients with cancer, and this incentive will support our ongoing efforts in this mission.

Chimeric Therapeutics R&D Tax Incentive Summary

Chimeric Therapeutics (ASX:CHM) has received a significant A$7.36M R&D tax refund from the Australian Government's R&D tax incentive program, acknowledging the company's R&D activities during the 2023 financial year. This funding will play a crucial role in advancing the development of Chimeric's diverse portfolio of cell therapies, including the innovative CAR T and NK cell therapies. With a focus on bringing the promise of cell therapy to more cancer patients, Chimeric remains committed to discovering, developing, and commercializing cutting-edge cell therapies. The receipt of this tax incentive underscores the company's dedication to advancing the field of cell therapy and its mission to provide potential cures for cancer patients.